Molecule News and Research

RSS

Injecting PAP may reduce chronic pain: Research

A study published in the Aug. 4, 2010 issue of the Journal of Neuroscience introduces an enzyme that could pack a big punch in the battle against chronic pain. Its name is prostatic acid phosphatase or PAP for short. According to researchers at the University of North Carolina at Chapel Hill, PAP blocks pain in animal models by siphoning off a molecule called PIP2—a critical component of the chemical cascade behind chronic pain.

5 Aug 2010

Scientists identify tiny RNA molecule that increases blood stem cells

Investigators have identified a new mechanism that controls the number of hematopoietic stem cells - cells that give rise to all blood and immune system cells. In a report in the online Early Edition of Proceedings of the National Academy of Sciences, researchers from Massachusetts General Hospital (MGH) and the Harvard Stem Cell Institute identify a tiny RNA molecule that increases the number of these blood stem cells, an advance that may improve treatment of blood system cancers.

5 Aug 2010

Scientist invents new approach to boost body's response to vaccinations

As the medical community searches for better vaccines and ways to deliver them, a University of Rochester scientist believes he has discovered a new approach to boosting the body's response to vaccinations.Richard P. Phipps, Ph.D., found that the same molecules used in drugs that treat diabetes also stimulate B cells in the immune system, pushing them to make antibodies for protection against invading microorganisms.

5 Aug 2010

Flow-induced polymer translocation through narrow and patterned channels

An octopus-like polymer can "walk" along the wall of a narrow channel as it is pushed through by a solvent. Now research in The Journal of Chemical Physics, which is published by the American Institute of Physics, provides a theoretical model that compares the transport characteristics of straight- and branched-chain polymers in smooth channels as well as in channels whose walls interact with the polymer -- work that could aid in the development of carrier molecules for delivering drugs at a controlled rate in the body.

4 Aug 2010

Infinity reports $18.4 million total revenue for second-quarter 2010

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today detailed recent developments in its product development portfolio and announced second quarter 2010 financial results.

4 Aug 2010

Study shows link between fructose and pancreatic cancer proliferation

Pancreatic cancers use the sugar fructose, very common in the Western diet, to activate a key cellular pathway that drives cell division, helping the cancer to grow more quickly, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found.

4 Aug 2010

Celera decreases second-quarter net loss to $6.1 million

Celera Corporation today reported net revenues of $32.6 million for the second quarter of 2010 that ended June 26, 2010, compared to $41.4 million for the prior year quarter. For the second quarter of 2010, Celera reported a net loss of $6.1 million, or $0.07 per share, compared to a net loss of $31.7 million, or $0.39 per share, for the prior year quarter.

4 Aug 2010

Simulations Plus releases MedChem Studio software for drug discovery

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, has announced the launch of its MedChem Studio™ software for drug discovery.

4 Aug 2010

Long-term dietary consumption of capsaicin can reduce blood pressure: Research

For those with high blood pressure, chili peppers might be just what the doctor ordered, according to a study reported in the August issue of Cell Metabolism, a Cell Press publication. While the active ingredient that gives the peppers their heat-a compound known as capsaicin-might set your mouth on fire, it also leads blood vessels to relax, the research in hypertensive rats shows.

4 Aug 2010

Scientists study specific cell interactions for reasearch on human developmental disorders

Two University of Iowa biologists have published a paper on how cells make specific interactions during development -- in the hope of one day learning more about human developmental disorders -- in the Aug. 2 issue of the journal Proceedings of the National Academy of Sciences.

4 Aug 2010

Curis reports net loss of $2.1 million for second-quarter 2010

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2010.

3 Aug 2010

Rigel reports net income of $27.0M for second-quarter 2010

Rigel Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2010.

3 Aug 2010

Caliper Life Sciences second-quarter GAAP revenue decreases 10% to $29.0 million

Caliper Life Sciences, Inc., today reported results for its second quarter ended June 30, 2010. Second quarter GAAP revenue decreased 10% to $29.0 million from $32.1 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 4% on a reported basis and 6% on an organic basis (which assumes constant currency).

3 Aug 2010

First patient treated in Phase Ib expansion study of CUDC-101

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase Ib expansion study for CUDC-101 in patients with advanced head and neck, gastric, breast and liver cancers.

3 Aug 2010

Telormedix, Swiss TPH Institute collaborate to develop effective vaccines for Malaria, Buruli Ulcer

Telormedix, a clinical stage biopharmaceutical company using targeted immunity to treat cancer and other diseases, today announced the start of a collaboration with the Swiss Tropical and Public Health Institute (Swiss TPH) on a pilot study using Telormedix's adjuvant, TMX-201, in connection with immunization for Malaria and Buruli Ulcer.

3 Aug 2010

Particles of iron oxide enhance tumor visibility through MRI

Tiny particles of iron oxide could become tools for simultaneous tumor imaging and treatment, because of their magnetic properties and toxic effects against brain cancer cells. In mice, researchers from Emory University School of Medicine have demonstrated how these particles can deliver antibodies to implanted brain tumors, while enhancing tumor visibility via magnetic resonance imaging (MRI).

3 Aug 2010

ArQule, Daiichi Sankyo announce decision to advance ARQ 197 into Phase 3 clinical trial for NSCLC

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with non-small cell lung cancer (NSCLC). In connection with this decision, the sponsor company, Daiichi Sankyo, will file a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for a trial comparing ARQ 197 plus erlotinib against erlotinib plus placebo.

3 Aug 2010

Neuroglobin may protect against Alzheimer's disease: Study

A team of scientists at the University of California, Davis and the University of Auckland has discovered that neuroglobin may protect against Alzheimer's disease by preventing brain neurons from dying in response to natural stress. The team published the results of their study in the April, 2010 issue of Apoptosis.

3 Aug 2010

BioMarin completes BMN 195 Phase 1 clinical trial for Duchenne muscular dystrophy

BioMarin Pharmaceutical Inc. announced today that it has completed the Phase 1 clinical study of BMN 195, a small molecule utrophin up-regulator, for the treatment of Duchenne muscular dystrophy (DMD). The Phase 1 clinical trial was a single-center, double-blind, placebo-controlled, single-dose escalation study followed by a multiple-dose escalation study in healthy volunteers.

3 Aug 2010

Osteologix grants Servier Research Group exclusive license to develop, commercialize NB S101

Osteologix, Inc. through its wholly owned Irish subsidiary Osteologix Limited and the Servier Research Group, the leading French independent pharmaceutical company, today announced that Osteologix has granted Servier an exclusive royalty bearing license to develop and commercialize NB S101 (strontium malonate) to treat post menopausal osteoporosis, other bone and joint disorders and dental indications worldwide, except in the U.S. NB S101 is an innovative molecule acting on both bone formation and bone resorption.

2 Aug 2010